Unique Clinical Trial Addresses Important Questions About Treating Cancer In Those With HIV
6/07/2011
As the world marks the 30-year anniversary of the first reporting of HIV/AIDS, now comes the realization of a new challenge for people with the incurable disease. For reasons not yet clear, people with HIV face a higher rate of cancers not usually associated with HIV. This increasing rate of "non-AIDS defining cancers" includes lung, head and neck, liver, kidney, and anal cancers, among others...
APP Pharmaceuticals To Market Letrozole Tablets, USP In The U.S.
6/07/2011
Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Letrozole Tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited (NSE: FKONCO) (BSE: 532545)...
New Strategy To Attack Tumour-Feeding Blood Vessels
6/07/2011
Professor Andreas Strasser from the Institute's Molecular Genetics of Cancer division has discovered a new strategy to attack tumour-feeding blood vessels. Scientists at the Walter and Eliza Hall Institute have discovered a key molecule needed to kill the blood vessels that supply tumours...
Eisai Inc. and Janssen, a Johnson & Johnson Company, both announced the presentation of data from the DACO-016 trial of DACOGEN® (decitabine) at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)...
News From The Journal Of Clinical Investigation: June 6, 2011
6/07/2011
HEMATOLOGY: Breaking down blood clots to beat DVT Deep vein thrombosis (DVT) is a serious medical condition in which a blood clot (also known as a thrombus) forms in one or more of the deep veins in the body, usually those in the legs. DVT can result in death if part of the blood clot breaks off and ends up blocking the major arterial blood vessels in the lungs...
4-D PET Image Reconstruction Enables Greater Cancer Detection
6/07/2011
A study introduced at SNM's 58th Annual Meeting is advancing a positron emission tomography (PET) imaging method that uses new 4D image reconstruction to achieve the highest diagnostic capability for the detection of cancer...
Preliminary research presented at SNM's 58th Annual Meeting is breaking new ground for the development of a brand new hybrid molecular imaging system. Simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI) is providing important diagnostic information about soft tissues and physiological functions throughout the body...
A study presented at SNM's 58th Annual Meeting focuses on the effect that breathing irregularities have on the accuracy of 4D positron emission tomography (PET) scans and outlines a PET imaging method that reduces "motion artifacts" or image blurring arising from respiratory motion...
Researchers are halting kidney cancer with a novel form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma. Patients with progressive kidney cancer receiving up to three doses of the therapy show dramatic slowing of cancer growth and stabilization of their disease...
Research introduced at SNM's 58th Annual Meeting could be a sign of hope for patients with neuroendocrine cancer not responding well to standard therapies. Most radiotherapies use medical isotopes that emit beta radiation. The therapy in this study employs alpha particles, which have potential for higher potency. In fact, one single atom could be enough to kill an entire cancer cell...